User:Kevin Buadlart Dagbay

From Proteopedia

proteopedia linkproteopedia link

One of the CBI Molecules being studied in the University of Massachusetts Amherst Chemistry-Biology Interface Program at UMass Amherst and on display at the Molecular Playground.

spinqualitylabelsall models Caspase-6 with Z-VAD-FMK, an inhibitor of caspase-6 activity Show:Asymmetric Unit Biological Assembly Drag the structure with the mouse to rotate   Export Animated Image

PhD Chemistry Student

University of Massachusetts Amherst Protein Regulation/Structural Biology of Caspase

Molecular Playground banner:

Contents 1 Caspase-6 and Neurodegeneration 2 Structure and Regulation 3 See Also 3.1 Crystal structure of ligand free human caspase-6 3.2 Crystal structure of human ligand-free mature caspase-6 3.3 Crystal structure of Caspase-6 zymogen 3.4 Crystal structure of active caspase-6 bound with Ac-VEID-CHO 4 References

Caspase-6 and Neurodegeneration

Cysteine aspartate proteases (caspases) play several key roles in cellular development, homeostasis, and a wide range of diseases. These proteases are normally expressed in cells as inactive precursor zymogens and get activated during processes such as cellular death pathway known as apoptosis [1]. Caspase-6 is particularly interesting since it has been implicated in neurodegenerative diseases including Alzheimer’s and Huntington’s Disease. Alzheimer’s Disease is the major cause of cognitive and cerebral deterioration in older adults. Caspase-6 has been shown to cut amyloid precursor protein (APP), at position 720 leading to the toxic fragment Jcasp, which is one of the fragments possibly responsible for causing the disease morphology [2]. Specific amino acid sequence (IVLD586G) is recognized by caspase-6 in mice with Huntington’s disease that give rise to the development of the behavioral and neuropathological features of the disease [3] [4]. Mutation of the caspase-6 site in mice model with Alzheimer’s and Huntington’s disease provides protection from the neural dysfunction, suggesting a causal relationship between caspase-6 cleavage and neurodegeneration.

Structure and Regulation

The structure of caspase-6 [5] [6] is similar in overall fold to the six other human caspases for which structures are available, all of which are dimeric when active. The structure of ligand-free caspase-6 differs significantly from all other caspases because two novel extended helices are observed flanking the caspase-6 active site. All caspases share a common active-site cysteine–histidine dyad [7] and derive their name, cysteine aspartate proteases, from the presence of the catalytic cysteine at the active site and from their exquisite specificity for cleaving substrate proteins after aspartate residues [8]. Caspases catalyze cleavage of amide bonds via nucleophilic attack of the cysteine thiolate (Cys163 in caspase-6) at the substrate amide carbonyl. During catalysis, the histidine (His121 in caspase-6) activates the catalytic cysteine and a water molecule. Mutation of either of these residues results in loss of catalytic activity [9]. Caspase-6 is expressed as inactive zymogen capable of dimerization. Caspase-6 has three reported cleavage sites that appear to be cleaved by autoproteolysis and or other caspases: D23 in the prodomain, D179 and D193 in the intersubunit linker [10]. The prodomain is released from the caspase dimer after cleavage leaving the active form of enzyme consists of two large and two small subunits. The large subunits contain the active site catalytic dyad residues, and the small subunits contain most of the dimer interface and the allosteric site.

The regulation of caspase-6 activity is not well studied. More research on possible ways to regulate caspase-6 activity will provide additional basic understanding of the mechanism of caspase-6 activation. In cells, caspase-6 can be activated by removal of the part of caspase-6, the prodomain, along with cleavage at specific amino acid residue (aspartate 193). In addition, an alternatively spliced form of caspase-6, the caspase beta (C6β) isoform has been shown to inhibit caspase-6 activity [11]. Morover, reported structures of caspase-6 and its inhibitors (Ac-VEID-CHO [PDB ID: 3OD5] & (Z-VAD-FMK [PDB ID: 3QNW]) shed the some basic dynamics of caspase-6 activation including loop rearrangement near the active site [12] [13].

See Also

• Caspase-6 at Wikipedia

Crystal structure of ligand free human caspase-6

2wdp

Crystal structure of human ligand-free mature caspase-6

3k7e

Crystal structure of Caspase-6 zymogen

3nr2

Crystal structure of active caspase-6 bound with Ac-VEID-CHO

3od5

References

• [1] Suzuki, A., Kusakai, G., Kishimoto, A., Shimojo, Y., Miyamoto, S., Ogura, T. et al. (2004). Regulation of caspase-6 and FLIP by the AMPK family member ARK5. Oncogene, 23, 7067–7075.
• [2] S.B. De and W. Annaert, Proteolytic processing and cell biological functions of the amyloid precursor protein. J. Cell Sci., 113 Pt 11 (2000), pp. 1857–1870.
• [3] C.L. Wellington, L.M. Ellerby, A.S. Hackam, R.L. Margolis, M.A. Trifiro, R. Singaraja, K. McCutcheon, G.S. Salvesen, S.S. Propp, M. Bromm, K.J. Rowland, T. Zhang, D. Rasper, S. Roy, N. Thornberry, L. Pinsky, A. Kakizuka, C.A. Ross, D.W. Nicholson, D.E. Bredesen and M.R. Hayden, Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract. J. Biol. Chem., 273 (1998), pp. 9158–9167.
• [4] C.L. Wellington, R. Singaraja, L. Ellerby, J. Savill, S. Roy, B. Leavitt, E. Cattaneo, A. Hackam, A. Sharp, N. Thornberry, D.W. Nicholson, D.E. Bredesen and M.R. Hayden, Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells. J. Biol. Chem., 275 (2000), pp. 19831–19838.
• [5] Baumgartner, R., Meder, G., Briand, C., Decock, A., D'Arcy, A., Hassiepen, U. et al., The crystal structure of caspase-6, a selective effector of axonal degeneration, Biochem. J. 423 (2009), 429–439.
• [6] S.V. Vaidya, E.M. Velázquez, G. Abbruzzese, J.A. Hardy, Substrate-Induced Conformational Changes Occur in All Cleaved Forms of Caspase-6. J. Mol. Bio., 406 (2011), 75-91.
• [7] Denault, J. B. & Salvesen, G. S. (2002). Caspases: keys in the ignition of cell death. Chem. Rev. 102, 4489–4500.
• [8] Chereau, D., Kodandapani, L., Tomaselli, K. J., Spada, A. P. & Wu, J. C. (2003). Structural and functional analysis of caspase active sites. Biochemistry, 42, 4151–4160.
• [9] Wilson, K. P., Black, J. A., Thomson, J. A., Kim, E. E., Griffith, J. P., Navia, M. A. et al. (1994). Structure and mechanism of interleukin-1à converting enzyme. Nature, 370, 270–275.
• [10] Klaiman, G., Champagne, N. & LeBlanc, A. C. (2009). Self-activation of Caspase-6 in vitro and in vivo: Caspase-6 activation does not induce cell death in HEK293T cells. Biochim. Biophys. Acta, 1793, 592–601.
• [11] Lee AW, Champagne N, Wang X, Su XD, Goodyer C, LeBlanc AC, Alternatively spliced caspase-6B isoform inhibits the activation of caspase-6A, J Biol Chem. 285 (2010):31974-84.
• [12] Muller, I. Lamers, MB., Ritchie AJ., Dominguez, C. Munoz-Sanjuan, I., Kiselyov, A. Structure of human caspase-6 in complex with Z-VAD-FMK: New peptide binding mode observed for the non-canonical caspase conformation, Bioorg Med Chem Lett., 18 (2011), 5244-7.
• [13] Xiao-Jun Wang, Qin Cao, Xiang Li, Kai-Tuo Wang, Wei Mi, Yan Zhang, Lan-Fen Li, Andrea C LeBlanc& Xiao-Dong Su, Crystal structures of human caspase 6 reveal a new mechanism for intramolecular cleavage self-activation, EMBO reports 11 (2010), 841-847.